Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Die nächste Sicherheitsgeneration: Quantenresistente Technologie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SS

WKN: A40D7S | ISIN: KYG8191L1169 | Ticker:
NASDAQ
16.11.26 | 18:40
0,690 US-Dollar
-3,35 % -0,024
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
SL SCIENCE HOLDING LIMITED Chart 1 Jahr
5-Tage-Chart
SL SCIENCE HOLDING LIMITED 5-Tage-Chart

Aktueller Chart SL SCIENCE Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
SL SCIENCE HOLDING LIMITED-Investoren interessieren sich auch für diese Wertpapiere
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareAdds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership PositionAdds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity FinancingIRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) ("Tarsus") today announced that it has entered into a securities purchase agreement with certain qualified...
► Artikel lesen
Immunome, Inc.: Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpoints...
► Artikel lesen
Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdateCompleted Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded...
► Artikel lesen
Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic ProtoporphyriaAligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission...
► Artikel lesen